Pulmonary arterial hypertension associated with systemic sclerosis

Research output: Contribution to journalArticle

Abstract

Systemic sclerosis (SSc) is commonly complicated by pulmonary arterial hypertension (PAH), which is a leading cause of death in the SSc patient population. Owing to the fact that the risk of developing pulmonary hypertension is high, screening is important, although the optimal modality remains to be defined. Furthermore, despite recent advances in therapy for PAH, the response to these interventions in patients with PAH with SSc has been discouraging. The lack of clinical response to these therapies may merely reflect the limitations of traditionally employed PAH outcome measures in SSc-PAH patients or highlight the heterogeneity of the disease manifestations within SSc. Importantly, since extrapulmonary involvement of the GI tract and kidneys by SSc limit candidacy for lung transplantation, new therapies that target abnormal cellular proliferation in the pulmonary vasculature are currently under investigation and may be particularly relevant to SSc-PAH.

Original languageEnglish (US)
Pages (from-to)267-279
Number of pages13
JournalExpert Review of Respiratory Medicine
Volume5
Issue number2
DOIs
StatePublished - Apr 2011

Fingerprint

Systemic Scleroderma
Pulmonary Hypertension
Lung Transplantation
Gastrointestinal Tract
Cause of Death
Therapeutics
Cell Proliferation
Outcome Assessment (Health Care)
Kidney
Lung
Population

Keywords

  • diagnosis
  • pulmonary hypertension
  • systemic sclerosis
  • therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Public Health, Environmental and Occupational Health

Cite this

Pulmonary arterial hypertension associated with systemic sclerosis. / Mathai, Stephen; Hassoun, Paul M.

In: Expert Review of Respiratory Medicine, Vol. 5, No. 2, 04.2011, p. 267-279.

Research output: Contribution to journalArticle

@article{2f0f0e3ae6064c89aedc340cc91dc9e8,
title = "Pulmonary arterial hypertension associated with systemic sclerosis",
abstract = "Systemic sclerosis (SSc) is commonly complicated by pulmonary arterial hypertension (PAH), which is a leading cause of death in the SSc patient population. Owing to the fact that the risk of developing pulmonary hypertension is high, screening is important, although the optimal modality remains to be defined. Furthermore, despite recent advances in therapy for PAH, the response to these interventions in patients with PAH with SSc has been discouraging. The lack of clinical response to these therapies may merely reflect the limitations of traditionally employed PAH outcome measures in SSc-PAH patients or highlight the heterogeneity of the disease manifestations within SSc. Importantly, since extrapulmonary involvement of the GI tract and kidneys by SSc limit candidacy for lung transplantation, new therapies that target abnormal cellular proliferation in the pulmonary vasculature are currently under investigation and may be particularly relevant to SSc-PAH.",
keywords = "diagnosis, pulmonary hypertension, systemic sclerosis, therapy",
author = "Stephen Mathai and Hassoun, {Paul M}",
year = "2011",
month = "4",
doi = "10.1586/ers.11.18",
language = "English (US)",
volume = "5",
pages = "267--279",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Pulmonary arterial hypertension associated with systemic sclerosis

AU - Mathai, Stephen

AU - Hassoun, Paul M

PY - 2011/4

Y1 - 2011/4

N2 - Systemic sclerosis (SSc) is commonly complicated by pulmonary arterial hypertension (PAH), which is a leading cause of death in the SSc patient population. Owing to the fact that the risk of developing pulmonary hypertension is high, screening is important, although the optimal modality remains to be defined. Furthermore, despite recent advances in therapy for PAH, the response to these interventions in patients with PAH with SSc has been discouraging. The lack of clinical response to these therapies may merely reflect the limitations of traditionally employed PAH outcome measures in SSc-PAH patients or highlight the heterogeneity of the disease manifestations within SSc. Importantly, since extrapulmonary involvement of the GI tract and kidneys by SSc limit candidacy for lung transplantation, new therapies that target abnormal cellular proliferation in the pulmonary vasculature are currently under investigation and may be particularly relevant to SSc-PAH.

AB - Systemic sclerosis (SSc) is commonly complicated by pulmonary arterial hypertension (PAH), which is a leading cause of death in the SSc patient population. Owing to the fact that the risk of developing pulmonary hypertension is high, screening is important, although the optimal modality remains to be defined. Furthermore, despite recent advances in therapy for PAH, the response to these interventions in patients with PAH with SSc has been discouraging. The lack of clinical response to these therapies may merely reflect the limitations of traditionally employed PAH outcome measures in SSc-PAH patients or highlight the heterogeneity of the disease manifestations within SSc. Importantly, since extrapulmonary involvement of the GI tract and kidneys by SSc limit candidacy for lung transplantation, new therapies that target abnormal cellular proliferation in the pulmonary vasculature are currently under investigation and may be particularly relevant to SSc-PAH.

KW - diagnosis

KW - pulmonary hypertension

KW - systemic sclerosis

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=79955383532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955383532&partnerID=8YFLogxK

U2 - 10.1586/ers.11.18

DO - 10.1586/ers.11.18

M3 - Article

VL - 5

SP - 267

EP - 279

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 2

ER -